Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)—are approved in Europe for metastatic colorectal cancer. Cyramza and Lonsurf are recent additions to the treatment armamentarium, and further options look set to penetrate the market in the next few years. Ever-increasing and ever-more-costly treatment options, as well as the evolution of biomarker-driven prescribing for colorectal cancer, and the costs that go with it, mean oncologists are striving to optimize the treatment algorithm and maximize treatment outcome for patients, while payers are balancing clinical need with economic constraints. This research analyzes the evolving prescribing landscape for metastatic colorectal cancer, and the impact of payer policy upon it.

Questions Answered

  • What are the current drivers of and barriers to prescribing of key brands for mCRC, and what are the main cost-related and clinical constraints on uptake?
  • How do European product labeling and national, regional, and local reimbursement restrictions differentially impact use of key brands in mCRC?
  • How might evolving healthcare reforms and cost-containment strategies affect reimbursement of novel agents? How challenging will country– and region-specific prescribing constraints be for uptake of these therapies?
  • To what extent will oncologists and payers embrace the costly emerging agents Keytruda (Merck & Co.), triplet combination binimetinib, encorafenib, and Erbitux (Array BioPharma/Pierre Fabre/Merck KGaA), and Tecentriq plus Cotellic (Roche)?

Product Description

Access & Reimbursement: Provides in-depth insight into the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Table of contents

  • Colorectal Cancer - Access & Reimbursement - Detailed, Expanded Analysis (EU5)

Author(s): Yulia Privolnev, MA

Yulia Privolnev is a manager on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Yulia’s specific focus is on all aspects of market access in Western and Eastern Europe, as well as external reference pricing (ERP) and managed entry agreements (MEAs) on a global scale. Yulia holds a bachelor’s degree from the University of Toronto and a master’s degree from the London School of Economics.

Related Reports

Colorectal Cancer - Geographic Focus - China - Colorectal Cancer - China In-Depth - China

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

View Details

Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

View Details

Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

Targeted therapies and various biomarkers (e.g., RAS,

View Details

Colorectal Cancer - Epidemiology - Mature Markets

DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of col...

View Details